Transform drug discovery with predictive human organ models
We are an organ-on-a-chip company that enables you to generate human-specific efficacy and safety data with pioneering PhysioMimix® single- and multi-organ solutions.
RECENT NEWS
FDA’s plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant methods
Areas to explore
New approach methodologies (NAMs), including Organ-on-a-chip (OOC), represent the key to faster, more accurate drug discovery. Explore how to harness the power of PhysioMimix® OOC in your lab, or via our contract research services.
Products
Learn more about PhysioMimix and why it’s helping drive OOC adoption
Applications
Explore the varying application areas that PhysioMimix OOC helps support
Resources
Dive deeper into our technology through app notes, scientific publications and much more
PhysioMimix®
Organ-on-a-chip
Our microphysiological systems model human-specific biology, which animals lack. Detect effects that manifest only in human tissue to improve the accuracy and efficiency of drug discovery.
- Human-relevant, translatable data
- Single- and multi-organ capabilities
- Flexible and customizable
- Easy to adopt, simple to use
- Broad drug modality compatibility, including monoclonal antibodies, oligonucleotides and traditional small molecules
What’s new?
Assay kit launch
DILI assay kit: Human 24
Predict more complex, latent and immune-related hepatotoxicity with our in vitro DILI assay kit: Human 24
Industry news
3Rs project with FDA
CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI
Partnerships
PhysioMimix data for Inipharm
PhysioMimix® Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment…
Press release
Pharmaron partnership
CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform